Your session is about to expire
← Back to Search
Other
ASP8062 for Alcoholism
Phase 2
Waitlist Available
Research Sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 3
Summary
This trial is testing a new drug called ASP8062 to see if it can reduce alcohol cravings in people with serious drinking problems. The goal is to find out if the drug helps reduce the urge to drink when exposed to alcohol-related cues.
Eligible Conditions
- Alcoholism
- Alcohol Consumption
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 3
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Alcohol Craving
Side effects data
From 2018 Phase 2 trial • 183 Patients • NCT0309272629%
Dizziness
15%
Headache
6%
Nausea
3%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ASP8062 30 mg
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active MedicationExperimental Treatment1 Intervention
Group II: Matching PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ASP8062
2021
Completed Phase 2
~330
Find a Location
Who is running the clinical trial?
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Lead Sponsor
836 Previous Clinical Trials
1,082,870 Total Patients Enrolled
457 Trials studying Alcoholism
823,886 Patients Enrolled for Alcoholism
Astellas Pharma IncIndustry Sponsor
695 Previous Clinical Trials
233,248 Total Patients Enrolled
Raye Litten, Ph.D.Study DirectorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)
Share this study with friends
Copy Link
Messenger